ViewRay postponed its initial public offering with which it planned to raise $52 million for its MRI-guided radiation therapy technology, Renaissance Capital reported.
Oakwood Village, Ohio-based ViewRay had planned to float 4 million shares at $12 to $14 apiece.
ViewRay’s MRIdian uses magnetic resonance imaging and Cobalt-60 radiation therapy to "locate, target and track the position and shape of soft-tissue tumors while radiation is delivered," according to the filing. In May 2012, the company won 510(k) clearance from the FDA for its MRIdian device, which won CE Mark approval in the European Union 2 years later, according to the filing.
It’s the latest medical device company to postpone or cancel an IPO recently. In early April Infraredx officially withdrew an IPO it hoped would raise $56 million, citing "unfavorable market conditions."
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.